Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
- EPS
- −40.0%
- Free cash flow
- +64.7%
Quarter to June 2026, against a year earlier
Follow BLTE
Alert me
Belite Bio, Inc. Sponsored ADR (BLTE) Free cash flow
Belite Bio, Inc. Sponsored ADR's free cash flow for fiscal 2025 was −$37.2M, compared with −$29.4M in fiscal 2024. Over the past ten years it has ranged from −$37.2M (fiscal 2025) to −$4.5M (fiscal 2020) — the current reading is the lowest in ten years. Belite Bio, Inc. Sponsored ADR ranks 384th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$37.2M | — |
| FY2024 | −$29.4M | — |
| FY2023 | −$29.9M | — |
| FY2022 | −$11.9M | — |
| FY2021 | −$7.5M | — |
| FY2020 | −$4.5M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Dec 2025 | −$10.6M | — |
| Sep 2025 | −$26.6M | — |
| Dec 2024 | −$4.6M | — |
| Sep 2024 | −$24.8M | — |
| 6 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $79.8M |
| BLTE Belite Bio, Inc. Sponsored ADR | −$66.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$101.2M |
| KOD Kodiak Sciences Inc. compare | −$159.9M |
| CGON CG Oncology, Inc. compare | −$179.3M |
| PTCT PTC Therapeutics, Inc. compare | −$259.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$308.9M |
| IMVT Immunovant, Inc. compare | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$567.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)